BioSpace News Archive

Oxurion NV announced that it has enrolled more than two-thirds of the planned total enrollment in its KALAHARI Phase 2, Part B clinical trial.

Adamis Pharmaceuticals Corporation announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update.

Decibel Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Prothena Corporation plc announced broad participation at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders being held March 28 – April 1, 2023 in Gothenburg, Sweden, highlighting Prothena’s leadership in advancing next generation treatments for Alzheimer’s and Parkinson’s disease.

Kezar Life Sciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

CONMED Corporation announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the KeyBanc Life Sciences and MedTech Investor Forum at 9:00 a.m. ET on Wednesday, March 22, 2023.

Sigilon Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 as well as certain other business highlights.

Roivant Sciences announced that it will host a live investor call and webcast at 8:00 AM ET on Wednesday, March 15 to review topline results from the ADORING 2 study, one of two replicate Phase 3 studies in atopic dermatitis.

GeneDx Holdings Corp., a leader in delivering improved health outcomes through genomic and clinical insights, reported its financial results for the fourth quarter and full year ended December 31, 2022.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that two abstracts have been accepted for poster presentations at the 2023 American Association for Cancer Research Annual Meeting taking place April 14-19, 2023, in Orlando, FL.